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Abstract
Cancer is one of the leading causes of morbidity and mortality around the world. Despite some success, traditional anticancer
drugs developed to reduce tumor growth face important limitations primarily due to undesirable bone marrow and cardiovascular
toxicity. Many drugs fail in clinical development after showing promise in preclinical trials, suggesting that the available in vitro and
animal models are poor predictors of drug efficacy and toxicity in humans. Thus, novel models that more accurately mimic the
biology of human organs are necessary for high-throughput drug screening. Three-dimensional (3D) microphysiological systems
can utilize induced pluripotent stem cell technology, tissue engineering, and microfabrication techniques to develop tissue models
of human tumors, cardiac muscle, and bone marrow on the order of 1 mm3 in size. A functional network of human capillaries and
microvessels to overcome diffusion limitations in nutrient delivery and waste removal can also nourish the 3D microphysiological
tissues. Importantly, the 3D microphysiological tissues are grown on optically clear platforms that offer non-invasive and nondestructive image acquisition with subcellular resolution in real time. Such systems offer a new paradigm for high-throughput drug
screening and will significantly improve the efficiency of identifying new drugs for cancer treatment that minimize cardiac and bone
marrow toxicity.
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Introduction
Current drug screening methods usually rely on twodimensional (2D) systems or animal models for assessment
of toxicity, pharmacokinetics, pharmacodynamics, and
organ system effects. While 2D cell culture lacks the inherent complexity of in vivo tissues in three-dimensional (3D)
arrangements, the intrinsically different biology of animal
models fails to capture the human-specific response to
drugs. To more accurately simulate the in vivo physiologic
human response to pharmacologic challenge, it is highly
desirable to replicate the complex 3D arrangements of
human cells, including, preferably, multiple organ systems
and a vascular supply. The vasculature not only provides
the necessary convective transport of nutrients and waste in
3D culture, but it also couples and integrates the response of
the multiple organ systems. Additionally, most drugs are

delivered to the target tissue through the microcirculation,
and thus incorporation of a vasculature best mimics in vivo
drug delivery.
Drug delivery to a target tissue depends on the function
of other organs. To achieve the desired effect of a selected
drug on a given tissue, the presence of multiple organ systems may be required. In chemotherapy, for example, the
gastrointestinal, circulatory, and urinary systems each contribute to determine the pharmacokinetics of a given drug.
If a drug possesses useful activity, it will be further studied
for possible adverse effects on major organs. While adverse
effects on the multiple organ systems throughout the body
are important, current anticancer therapies are mostly limited by their undesirable side effects on the immune system,
the cardiovascular system, and the liver. First-pass drug
metabolism in the liver prior to entry into the vascular

system can markedly influence the toxicity of a wide range
of drugs. However, in cancer treatment it is well established
that the majority of antiproliferative agents used in traditional chemotherapy can cause myelosuppression in a
dose-dependent manner (e.g. alkylating agents, pyrimidine
analogs, anthracyclines, methotrexate, etc.).1 The use of
hematopoietic growth factors has significantly improved
the primary acute myelosuppression observed during
anticancer treatments;2 however, in some patients these
growth factors can also mask development of a latent residual bone marrow injury manifested by a decrease in hematopoietic stem cell (HSC) reserves and an impairment in
HSC self-renewal.3 Regarding the cardiovascular system,
systemic anticancer therapy can lead to hypertension,
thromboembolic events, left ventricular dysfunction, myocardial ischemia, arrhythmias, and pericarditis.4–6 In this
regard, two types of cardiotoxicity have been well established according to the type of damage in the cardiomyocyte: type I-induced cardiotoxicity (e.g. induced by
anthracycline), which is dose dependent and associated
with myocyte death; and, type II-related cardiotoxicity
(e.g. induced by trastuzumab), which is less predictably
associated with dose, and typically correlated with reversible myocardial dysfunction rather than histological
changes or myocyte death. However, with the increase of
a wide range of new anticancer agents used in molecularly
targeted therapy, an unintended cardiotoxicity, recently
classified as ‘off-target,’ has arisen from many of these compounds. Off-target cardiotoxicity results from the inherent
challenge of targeting molecules such as specific kinase
inhibitors. Although inhibition of specific kinases is effective in treatment of some cancers, kinase inhibitors are a
relatively ubiquitous class of molecules that can unintentionally affect non-cancerous tissues, especially cardiac
tissue. This new class of drugs has increased the risk and
need for assessment of chemotherapy-associated
cardiotoxicity.1–3,6
To address the need for improved preclinical drug toxicity models, we are developing a system for high-throughput screening of both drug efficacy and organ-specific
toxicity. Our system features 3D tissues made entirely of
human cells. The tissues are connected and perfused by
human microvessels. Initial designs incorporate tumor, cardiac, and bone marrow tissue modules that allow assessment of anticancer drug efficacy as well as potential side
effects.

Pharmacology
Once a new drug target has been identified, a sequence of
studies is initiated to characterize the dose–response relationship prior to clinical trials. A variety of assays at the
molecular, cellular, organ, and systemic levels are needed
to define the pharmacokinetics and pharmacodynamics of
the drug. Pharmacokinetics is the study of changes in drug
concentration with time due to absorption, distribution,
metabolism, and elimination of the drug. In contrast,
pharmacodynamics is the study of the drug concentration-dependent tissue or cell response. The target tissue is
normally represented by a dose–response curve. The EC50

of a drug is an index of its sensitivity or potency and refers
to the concentration required to produce 50% of that drug’s
maximal effect (e.g. tumor reduction or antiproliferative
effect in response to an anticancer agent). The maximal efficacy of a drug represents the upper limit of the dose–
response relation on the response axis.
In cancer treatment, the same total drug dose can be
delivered over different lengths of time (i.e. different dose
intensities), which can impact the effect of the drug on other
organ systems. The goal of chemotherapeutics is to achieve
a desired effect with minimal adverse side effects; therefore,
when designing a microphysiological system for drug
screening, it is important to recognize that many anticancer
drugs are limited by their adverse effect on a number of
non-cancerous tissues throughout the body. As further
introduced below, the proposed system recognizes that
the response of cells and tissues to a pharmacologic challenge is greatly influenced by the microenvironment.
Table 1 categorizes a wide range of important microenvironmental factors that are present in the 3D architecture of
the tissue that influence tissue response to a drug.
Drug behavior in 2D versus 3D systems
Differences in cell morphology, differentiation, proliferation, viability, response to stimuli, metabolism, and
gene/protein expression are observed when cells, previously cultured in 2D, are moved to a 3D environment.7
This is not surprising considering that human organs,
with few exceptions, need 3D structure to develop their
associated functions.8,9 A well-known example of the necessity of 3D models for testing toxicity of novel therapeutics is
the culture of hepatocytes, which behave quite differently in
2D versus 3D cultures.10
In cancer research, the idea of mimicking 3D tissue function in vitro is not new. Tumor spheroids, for example, were
presented nearly four decades ago.11 However, given the
fact that 2D systems are relatively easy to culture, provide
simple assessment of cell function (e.g. protein expression),
and are lower in cost, the adoption of 3D systems has been
relatively slow. Nevertheless, recent studies have enhanced
our understanding of the necessity for testing the efficacy of
anticancer drugs in 3D systems. For example, among other
differences, tumor cells in 3D adopt a different morphology
than in 2D,12 have different cell surface receptor expression
and proliferation;13differentially regulate genes responsible
for angiogenesis, cell migration, and invasion;14–16 and have
different extracellular matrix (ECM) synthesis.17
Importantly, tumor cells in 3D also show differences in
anticancer drug sensitivity. Studies have shown that culturing cancer cells in 3D can shift their dose–response, sometimes to the point where they become functionally resistant
to the drug. For instance, culturing of cancer cells in a 3D
system can lead to an increase of 20-fold or more in the EC50
compared with 2D culture when cancer cells are exposed to
doxorubicin.18 Moreover, recent studies suggest that 3D
models, unlike 2D culture, more accurately predict
acquired drug resistance.19 Drugs that target molecular
pathways have shown differences in activation or inhibition
depending on the 3D architecture of the local

Table 1 Drug testing of tumor cells cultured in 3D
Tumor cell line

Outcome of drug treatment

Refs.

I. 2D vs. 3D culture systems – Examples of observed differences in drug response
Ia. Cancer cells cultured in 3D are more resistant to anticancer drugs compared with 2D
HepG2 human liver hepatocellular carcinoma
cells

Responses of cells to cisplatin, 5-fluorouracil and
doxorubicin (anticancer drugs) showed higher
EC50 values in 3D multicellular spheroids compared
with 2D monolayer. The 3D model conferred differentiated phenotypes including increased cell–
cell adhesion, G1 phase cell cycle arrest, and
enhanced cellular resistance to apoptosis

Li et al.98

SA87 (brain metastases), NCI-H460 and
H460M (lung) lines from primary tumors and
metastases

Responses of cells to increasing concentrations of
anticancer drugs such as doxorubicin and 5fluorouracil showed that 3D models conferred
more resistance to the drugs than the usual
monolayer culture system. The anticancer drugs
were efficient after 24 h of treatment in the monolayer cultures, whereas they were significantly
efficient after only 1 week of incubation in the 3D
systems

David et al.99

TE2 and TTn human esophageal squamous
carcinoma lines

Responses of cells to anticancer drugs such as cisplatin and doxorubicin showed higher EC50 values
in 3D cultured cells compared with 2D demonstrating a higher increase of drug resistance in 3D
models

Fujiwaraet al.100

MCF-7 breast cancer cells

The antiproliferative effect of different anticancer
agents including doxorubicin, paclitaxel, and
tamoxifen in 3D models was significantly lower
than in 2D monolayer by a 12- to 23-fold difference
in their EC50 values. The greater synthesis of collagen in 3D suggested that the ECM can act as a
barrier to drug diffusion

Horning et al.18

Ib. Cancer cells cultured in 3D makes them resistant or desensitizes the cancer depending on the cell and/or drug type
C4-2B bone metastatic prostate cancer cells

Responses of cells to camptothecin, docetaxel, and
rapamycin (anticancer drugs), alone and in combination, differed between the 3D and 2D monolayer systems

Gurski et al.101

HT29, SW620, SW1116 (colon) UM-SCC-22B
(head and neck), and A2780 (ovary) solid
tumor cell lines

Responses of cells to anticancer drugs such as cisplatin and miltefosine showed that multilayers are
more resistant to the drugs than the corresponding
monolayers. However, there are substantial differences between the drugs depending on culture
conditions

Padron et al.102

A549 and H358 lung cancer cell lines

Potency and efficacy from a set of 10 anticancer drugs
including paclitaxel, doxorubicin, vinorelbine,
gemcitabine, or cisplatin showed significant differences when tested in 3D cultured cells comparing with traditional 2D cultures. The activity of these
drugs varied with individual drugs and the cell line
used for testing

Nirmalanandhan et al.103

Ic. Anticancer drugs demonstrate different effectiveness in 3D compared with 2D. ECM involvement and selective pathway interaction differences
U87 (glioblastoma), PC3 (prostate), T47D
(breast), and HCT116 (colon) human cancer
cell lines

Cells exposed to both PX-866 and wortmannin
phosphatidylinositol-3-kinase inhibitors suppressed 3D spheroid growth at low concentrations,
unlike in 2D monolayer which failed to inhibit cell
growth even in higher concentrations

Howes et al.21

AU565, SKBR3, HCC1569, and BT549 HER2amplified breast cancer cell lines

Drug response to trastuzumab and pertuzumab (two
anti-HER2 agents) was highly dependent on
whether the cells were cultured in 2D monolayer or
3D laminin-rich ECM gels. Inhibition of b1 integrin
significantly increased the sensitivity of the HER2amplified breast cancer cell lines to the drugs when
they grow in a 3D environment.

Weigelt et al.22

(continued)

Table 1 Continued
Tumor cell line

Outcome of drug treatment

Refs.

Ishikawa, RL95-2, KLE endometrial cancer cell

3D multicellular cultures exposed to the anticancer
agents such as doxorubicin and cisplatin exhibited greater resistance to the drugs than 2D
monolayers. Their effects on the intracellular
mediators were not similar in 3D and 2D cultures,
including selective paradoxical stimulatory effects
on VEGF secretion. Differences were also
dependent on cancer cell lines.

Chitcholtan et al.20

II. ECM environment – Examples of observed differences in drug response
IIa. The ECM that surrounds the tumor cells impacts pharmacodynamics
HT1080 human fibrosarcoma cells

The anti-invasive effect of doxorubicin observed in
conventional 2D culture was completely abolished
in a 3D environment. The 3D collagen type I matrix
inhibited the antimigratory effect of the drug

Millerot-Serrurot et al.24

H1299, PC3, HCT116 colon cancer cells

3D cultured cells treated with 5-fluorouracil resulted
in p53 stabilization and angiogenesis inhibition by
increasing the production of arresten, a collagen
IV-derived fragment that possesses antiangiogenic
activity. The presence of ECM contributed to the
antiangiogenic effect of an anticancer drug

Assadian et al.23

MIA PaCa-2, PANC-1, and Capan-1 pancreatic
cell lines

Cancer cell lines adhering to ECM proteins (collagen I,
collagen IV, fibronectin, and laminin) showed
decreased cytotoxicity of anticancer drugs such as
doxorubicin, cisplatin, and 5-fluorouracil, but not
gemcitabine

Miyamoto et al.104

III. Other cell types in the 3D microenvironment – Examples of observed differences in drug response
IIIa. Interactions with stromal cells involved in drug sensitivity and development of drug resistance
T3M4 and PT45-P1 pancreatic carcinoma cell
lines and murine pancreatic fibroblasts

Tumor cell lines cultured in presence of fibroblasts
became much less sensitive toward treatment with
the anticancer agent etoposide. Fibroblasts contribute to the development of chemoresistance via
increased secretion of NO and release of IL-1 by the
tumor cells

Muerkoster et al.105

Different human cancer and NIH3T human
fibroblast

Fibroblast-derived 3D matrix increased b1-integrindependent survival of a subset of human cancer
cell lines during taxol treatment, while it sensitized
or minimally influenced survival of other cells

Serebriiskii et al.106

IIIb. Presence of ECs are necessary for tumor growth and progression, and also influence the optimal or impaired drug delivery to the tumor tissue
Observation

Refs.

ECs, beside providing the blood supply to the tumor that allow it to grow and progress, are also responsible for
carrying therapeutic drugs to reduce it

Carmelie and Jain25

Antiangiogenic drugs used as a therapeutic strategy must be examined further in order to find a balance between
therapeutic efficacy and excessive vascular regression preventing adequate drug delivery

Goel et al.107

The use of vascular disrupting agents can reduce tumor growth and progression by inducing occlusion of the
tumor vasculature, which in turn leads to tumor necrosis

Thorpe108

IV. Other factors in a 3D complex that might influence drug response
IVa. Hypoxia and drug transporter expression
Tumor cell line

Outcome of drug treatment

Refs.

MCF7 breast cancer cells

3D cultured spheroids, unlike in 2D monolayer,
showed an increase in the multidrug resistance
transporter Pgp via activation of hypoxia inducible
factor (HIF-1) which contributes to increased
doxorubicin drug resistance

Doublier et al.19

WiDr colon cancer cells

Cells cultured as multilayer have a lower uptake of
antifolates, including the anticancer drug methotrexate, compared with monolayers. This higher
resistance may be related to a decrease in the
reduced folate carrier drug transporter when cells
are cultured in 3D.

Peters et al.109

(continued)

Table 1 Continued
Tumor cell line

Outcome of drug treatment

Refs.

HT29 human colon cancer cells

3D multicellular layers are necessary to predict
hypoxia-activated anticancer drugs such as tirapazamine since their diffusion through the extravascular tumor compartment may limit their activity

Hicks et al.110

3D spheroids cultured in flow showed a threefold
increase in resistance to doxorubicin
compared to monolayer cells cultured under static
conditions

Agastin et al.111

IVb. Vascular shear stress
Colo205 colon human cancer cells

V. Example of other organs affected by the need of a 3D complex in response to an optimal drug screening
Cell line

Outcome of drug treatment

Refs.

Primary human hepatocytes (PHH)

For testing toxicity of novel therapeutics, the culture of
hepatocytes needs a 3D complex to retain their
functions and predict hepatotoxicity, since they
quickly stop producing drug metabolizing enzymes
when cultured on a 2D monolayer

Schyschka et al.10

Mammary epithelial cells

The cell matrix interactions in 3D are critical to recapitulate the structure and function of the mammary
gland. Drug sensitivity of mammary epithelial cells
cultured in 3D and in 2D showed significant
differences

Roskelley et al.9 and
Chen et al.112

microenvironment.20–22 In addition, the composition of the
ECM can significantly affect the antimigratory effect of
some drugs.23,24 These examples demonstrate that tumor
cell biology in 3D culture is significantly different than
2D, leading to differences in drug efficacy. Although
in vitro, the results in 3D culture may be more representative
of the way cancer cells in vivo respond to chemotherapeutic
treatment. Table 1 summarizes and highlights the role that
the ECM, stromal cells (e.g. fibroblasts), vasculature, and
other factors present in the tumor microenvironment can
play in modulating drug response, sensitivity, and drug
resistance.
The drug response differences between 2D and 3D
models suggest that pathways necessary for survival in a
3D environment may not be activated in 2D. As a result,
drug screening performed on 2D monolayers can increase
the false-positive and false-negative rates of investigational
compounds. While false-positive results can increase failure
of drugs in clinical trials, false-negatives discard potentially
effective drugs. The use of 3D microphysiological systems is
predicted to reduce the rate of false-positive and falsenegative outcomes, thereby reducing the need for animal
testing and improving the overall efficiency of drug
discovery.
Drug panel and strategy for validation
Microphysiological systems need to exhibit drug responses
that parallel those seen in vivo. Our strategy for validating
tissue responses includes a panel of common drugs
(Table 2). The panel distinguishes drugs considered to be
traditional chemotherapy from those that can be classified
as molecularly targeted therapy and considers known and

poorly understood cardiac muscle and bone marrow toxicity. The panel also recognizes other important observed
effects in order to validate, predict, and better understand
the response, toxicity, and effectiveness of the drug.

Design of in vitro microphysiological systems
To address the numerous potential side effects of anticancer
drugs on multiple tissues and organ systems, robust in vitro
microphysiological systems have been developed for preclinical high-throughput screening of candidate drugs.
These systems need to mimic critical functions and anatomical features of in vivo tissues to generate an appropriate
response to a pharmacologic challenge. It is important to
note that because of the complex nature of in vivo tissues, it
may be impractical and unnecessary to mimic all the functions and architecture of in vivo tissues. In this view, an
optimal level of anatomical complexity that has bearing
on drug distribution and response of in vivo tissues needs
to be reflected in the microphysiological systems.
Each specific organ system presents unique challenges to
correlate in vitro performance with in vivo physiology and
pathology associated with anticancer drugs. The following
sections discuss the critical features of major organ systems
and their anticancer drug-related behavior. Methods for
mimicking these features in vitro within the proposed
microphysiological platform are also presented.
Vascular system
One of the most prominent features of all human tissues is
vasculature, which provides a convective mode of transport
for nourishment and waste removal. The Vascular transport

Table 2 Example drug panel – Strategy for validation.
Target

Approved drug

Outcome of drug treatment

I. Physiologic validation of cardiac muscle and microvasculature function
Ia. Cardiac muscle validation. Example of representative drugs for cardiac validation
L-type Ca2þ channel

b-adrenergic receptor

Verapamil; L-type Ca2þ
channel blocker
(negative inotrope)
Epinephrine; b-adrenergic receptor agonist
(positive inotrope)
Propranolol; b-blocker
(negative inotrope)

Human ether-a-go-go
related gene (hERG)
channel

Dofetilide; hERG channel blocker

b-adrenergic receptors agonists
are associated with a proliferative and angiogenic effect113
b-blockers potentiate antiproliferative and antiangiogenic
effects in tumor and ECs114
Undesirable blockade of hERG
channel represents the most
common form of drug-induced
QT prolongation associated
with risk of arrhythmias and
possible sudden death115
hERG channels are expressed in
several tumor cells influencing
their activity in cell survival and
proliferation116,117

Ib. Microvasculature validation. Example of representative drugs for vascular validation
Vascular permeability

Thrombin; permeabilizing agent
VE-cadherin
disruption118

Vascular permeability is greatly
increased in tumor vasculature
resulting in leaky and dysfunctional vessels119

II. Physiologic validation of tumor tissue reduction
IIa. Tumor tissue validation. Example of representative drugs used in traditional chemotherapy
Target

Approved drug

Risk of direct cardiotoxicity/
bone marrow toxicity
(reviewd previously
by1,4,6,120,121,122)

Outcome of drug treatment

DNA intercalator

Doxorubicin
(anthracycline)

Recognized risk of cardiotoxicity
Myelosuppression. Recognized
bone marrow injury

Platinum analog

Cisplatin, oxaliplatin

Anti-metabolite

5-fluoruracil

Mitotic disruptor

Vincristine
(vinca alkaloid)

Possible cardiotoxicity
Myelosuppression and recognized bone marrow injury
Possible cardiotoxicity associated
with myocardial ischemia and
arrhythmia
Recognized bone marrow injury
Low recognized cardiotoxicity
Myelosuppression and recognized bone marrow injury

Typical cardiotoxicity type I
associated with ROS generation and irreversible cell
damage.
Differently described behavior in
2D vs. 3D-complex (Table 1)
Differently described
behavior in 2D vs.
3D-complex (Table 1)
Differently described
behavior in 2D vs.
3D-complex (Table 1)
Possible cardioprotection by
attenuation of doxorubicininduced cardiac myocyte
toxicity123

IIb. Tumor tissue validation. Example of representative drugs used in molecularly targeted chemotherapy
Target

Approved drug

Risk of direct cardiotoxicity

Outcome of drug treatment

Growth factor receptors,
intracellular signaling
pathways, possible
channel targets, and
other cell functions

Small molecule tyrosine
kinase and multikinase inhibitors

In general, possible different
drug response in 2D vs. 3D
complex due to the differentially 3D activated or inhibited
pathways compared with 2D

HER2

Trastuzumab
(monoclonal antibody)

Cardiomyocyte survival, contraction dysfunction, or QT prolongation
Reviewed by Hedhli and Russell5,
Force et al.124, and Raschi and
De Ponti125
Recognized risk of cardiotoxicity

Typical type II cardiotoxicity and
‘on-target’effect126,127
Differently described drug
response in 2D vs. 3D-complex (Table 1)

(continued)

Table 2 Continued
Target

Approved drug

Outcome of drug treatment

HER2

Lapanitib

Low risk of cardiotoxicity

EGFR

Gefinitib

Low risk of cardiotoxicity

VEGFR, c-KIT, PDGFRa/
b, RET, CSF-1R, FLT3
(hERG)

Sunitinib

Recognized risk of cardiotoxicity

RAF, VEGFR, c-KIT,
PDGFRa/b, FLT3

Sorafenib

Recognized risk of cardiotoxicity

BCL:ABL, PDGFRa/b,
c-KIT, (hERG)

Imatinib

Recognized risk of cardiotoxicity

Strong warning for QT prolongation, risk of arrhythmia, and
sudden death
Possible hERG blockade by ABL
inhibitors115

mTOR

Everolimus

Warning risk of cardiotoxicity
(lack of significant published
data)

Warning for QT prolongation
Additional possible HIF-1 activity inhibition under hypoxic
conditions (3D tumor
environment)128

Proteasome inhibitor
26 S

Bortezomib

Warning risk of cardiotoxicity

Hypotension, warning for QT
prolongation.
Additional HIF-1 transcription
inhibition under hypoxic conditions (3D tumor
environment)129

HDAC1, 2, 3, 6

Vorinostat

Warning risk of cardiotoxicity

Warning for QT prolongation
Additional HIF-1 degradation
induction under hypoxic
conditions by HDAC inhibitors (3D tumor
environment)130

No risk of cardiotoxicity as there
is with the monoclonal antibody that targets the same
receptor.
Different signaling pathways are
activated in cardiomyocytes
by both strategies124
Typical ‘off-target’ effect
PDGFR signaling important in
cardiomyocyte survival
ATP depletion by mTOR
increases activity in
cardiomyocytes124

III. Physiologic validation of EC proliferation and migration/angiogenesis
IIIa. Angiogenesis validation. Example of representative drugs used in molecularly targeted chemotherapy
Target

Approved drug

Risk of direct cardiotoxicity

Outcome of drug treatment

Growth factor receptors,
intracellular signaling
pathways, and possible channels targets

Small molecule tyrosine
kinase and multikinase inhibitors

Cardiomyocyte survival, contraction dysfunction or QT prolongation
Reviewed by Hedhli and Russell5,
Force et al.124, and Raschi and
De Ponti125

In general, possible different
drug response in 2D vs. 3D
complex due to the differentially 3D activated or inhibited
pathways compared with 2D

VEGF
(growth factor)

Bevacizumab
(monoclonal antibody)

Warning risk of cardiotoxicity

Disrupting VEGF signaling, most
of these drugs exhibit predictable risk of hypertension
and thrombosis (cardiovascular indirect side effects)
since VEGF does not just help
new vessels grow, but also
protects existing blood
vessels131,132

VEGFR, c-KIT, PDGFRa/
b, RET, CSF-1R,
FLT3, hERG

Sunitinib

Recognized risk of cardiotoxicity

VEGFR, EGFR, RET

Vandetamib

Warning risk of cardiotoxicity

VEGFR, PDGFRa/b, cKIT

Pazopanib

Warning risk of cardiotoxicity

is particularly necessary for tissues with a diameter greater
than 200 mm,25–27 as passive diffusional transport is inefficient. Thus, to replicate the complex 3D arrangement of
cells and ECM, human microphysiological systems must
include a vasculature made of perfused vessels that possess
a physiologic flow. The molecular transport across the vascular wall into normal tissues is largely driven by diffusion,
but limited convection also takes place primarily in capillaries. Vascular permeability varies considerably among
different tissues and is modulated by different factors
such as blood flow.28 Vascular permeability undergoes significant changes in pathological conditions such as wound
healing, chronic inflammatory diseases, and cancer.25
Unlike arteries and veins, capillaries consist of little more
than a layer of endothelial cells (ECs) and connective tissue,
along with a sparse covering of pericytes. They lack the
smooth muscle cells that are present around the major vessels, arteries, and veins. The ECs are embedded in a 3D
microenvironment that mainly consists of a collagenbased ECM and pericytes, and is influenced by biochemical
(i.e. growth factors) and physical (i.e. shear stress) forces.
Mimicking this complex microenvironment in vitro is a
major challenge in vascular research. ECs are responsible
for regulating a variety of functions including vascular tone,
inflammation, coagulation, and sprouting of new vessels. In
normal physiological conditions, vasculature is vasodilatory, antithrombotic, anti-inflammatory, and nonangiogenic. These functions are controlled mainly by
secreted factors from the EC.29 In this context, since ECs
are mostly quiescent under physiological conditions, the
development of new anticancer treatments is also directed
toward targeting cell signaling pathways involved in pathological EC proliferation and migration.5 By targeting endothelium, the vascular supply to tumor tissue can be
reduced, thereby inhibiting tumor growth. Antiangiogenic
drugs are mostly targeted to the vascular endothelial
growth factor (VEGF) signaling pathway. These drugs
often have VEGF receptors (VEGFRs) as a common target.
However, VEGF does not only help new vessels to grow, but
it also protects existing blood vessels. Thus, due to disruption of VEGF signaling, many of these drugs are associated
with a predictable risk of hypertension and coagulation that
can lead to vascular dysfunction and thrombosis,
respectively.4,7,30
Tumor tissue
Tumor cells have a remarkable ability to evolve in response
to communication with the microenvironment. In this view,
drug testing merely on isolated cancer cells is insufficient
for a reliable estimation of drug efficacy in humans. The
quest to develop improved models has progressed from
2D cancer cell culture to 3D tumor spheroids made up of
cancer cells and 3D tumor spheroids composed of a mixture
of cancer and stromal cells.31–33 However, these models lack
perfused vasculature and are limited in their ability to
mimic the in vivo microenvironment critical for modeling
drug delivery. Hence, we believe in vitro tumors with perfused capillaries, embedded in naturally occurring ECM,
will produce improved drug screening studies.

It is widely accepted that tumors actively communicate
with vasculature to fulfill their growing metabolic
demands, and in some cases to metastasize. Such communication brings several changes in vasculature, including
angiogenesis mediated by VEGF, increased vascular leakiness, and irregular vascular interconnections.25,34,35 In addition, it is noted that lymphatic vasculature of tumors is
generally dysfunctional.34,36,37 Together, these conditions
are believed to increase the interstitial fluid pressure of
tumors and consequently, increase the interstitial fluid
flow from the tumor into surrounding tissue.34,38,39 As a
result, in vivo tumors display uneven distribution of cytokines, nutrition, and drugs across the tissue, posing a major
challenge for efficient drug delivery.34,38–40 Therefore, to
simulate a variety flow and pressure conditions, drug
screening platforms need to have control over spatiotemporal resolution of interstitial flow and pressure in tumoron-chip devices.
The inefficient vascular supply to tissues and increased
growth rate create hypoxic conditions in certain regions of
tumors. As a result, the microenvironment remains acidic,
adversely affecting the action of many chemotherapeutic
drugs as reviewed elsewhere.41,42 Hypoxia also promotes
epithelial-to-mesenchymal transition, which is marked by
increased motility of cancer cells and results into invasion of
surrounding tissue.43 Further, hypoxia is believed to promote chemotherapeutic drug resistance in cancer cells by
gene expression products such as P-glycoprotein.44 Hence,
the in vitro tumors need to grow under hypoxic conditions
closer to that experienced in vivo. We, and others, have previously developed a protocol for creating normal tissues
that are perfused with dynamic vasculature under hypoxic
and non-hypoxic conditions.45–47
Interstitial flow and pressure, cellular behavior, drug distribution, and, in turn, drug efficacy are influenced by ECM,
which constitutes a major part of the tumor tissue. Tumors
are characterized by stiff ECM, which is typically composed
of collagen, fibronectin, glycosaminoglycans, and proteoglycans.48,49 The active role of tumor ECM in cell signaling,
as well as creating chemical and mechanical cues for cell
migration, is reviewed elsewhere.48,50 Interestingly, it has
been shown that it is possible to extract acellular ECM
from in vivo tumors,51,52 and it is also possible to achieve
collagen of varying stiffness by mixing it with other naturally occurring ECM such as fibrin. We believe such strategies could be implemented to create microphysiological
tumor tissue.
Apart from the constituents of the tumor microenvironment discussed earlier, other major components are
immune cells and tumor-associated fibroblasts.50,53,54 We
and others have shown that fibroblasts secrete factors
necessary for creating perfused vasculature,46,47,55 and,
recognizing this fact, our current model of perfused network includes fibroblasts.45,47 However, for the future
advancement of the in vitro tumor model, appropriate
tumor-associated fibroblasts may be needed. Among the
immune cells, tumor-associated macrophages are perhaps
the most significant cells as they affect a plethora of cancer
processes, including angiogenesis, invasion, and metastasis,50,53,56 and, importantly, they also adversely affect the

chemotherapy.56 Hence, we believe that for future advancement of microphysiological tumor tissue, it is important to
integrate immune cells, particularly macrophages, on
organ-on-chip platforms.
Cardiac tissue
Cardiotoxicity and altered cardiac function have been identified as significant side effects of anticancer drugs.4,57–60 At
the cellular level, anticancer drugs can cause DNA damage,
adenosine triphosphate (ATP) depletion, apoptotic protein
release, reactive oxygen species (ROS) generation, electrolyte imbalance, lipid accumulation, and myocyte
death.4,59–61 At the tissue level, these effects manifest as
vasospasm, changes in force and frequency of contraction,
and modified electrophysiology.4,59 As a result of these cell
and tissue level effects, whole organ pathologies, such as
left ventricular dysfunction, heart failure, myocardial ischemia, arrhythmias, and pericardial disease,4,57–60,62 are realized. These cardiac dysfunctions are often not discovered
until clinical trials primarily due to limitations in current
drug screening models. Similar to the previous discussion,
cardiac animal models provide whole heart response to
drugs, but many drugs have human specific effects.
The key features of a microphysiological cardiac tissue
system are as follows: (1) Use of a cardiac-specific matrix
creates a 3D environment with the appropriate tissuespecific architecture to induce the formation of tissue that
better mimics in vivo physiology and pathology.63 (2) All
cells are of human origin allowing assessment of human
cell-specific drug responses. With further development of
lineage-specific differentiation protocols, all cells implanted
in the device may be derived from the same induced pluripotent stem cell line allowing for genetic homogeneity, and
thus patient-specific responses, throughout the tissue compartments. (3) Tissues exhibit synchronous and rhythmic
spontaneous contraction that allows detection of alterations
in electrophysiological and contractile properties. Together,
these properties represent the most critical parameters for a
high-throughput cardiac tissue module for the screening of
drug-induced cardiac side effects.
Bone marrow
Toxicity of pharmacological agents toward HSCs is a major
problem for many therapeutic strategies, including cancer
chemotherapy.64,65 Many antineoplastic drugs directly
target the machinery of cell proliferation and thus also
target HSC, which can be either quiescent, undergoing
self-renewal, or differentiating into erythroid, myeloid, or
lymphoid progenitors, or they may target more committed
progenitors downstream of HSC.66 This results in immunosuppression, anemia, and thrombocytopenia, and many
patients develop infections as a result. Blood transfusions
can reverse anemia, and neutropenia can be addressed by
treatment with granulocyte-colony stimulating factor
(G-CSF). However, in severe cases of myelosuppression,
patients have to undergo bone marrow transplantation –
either restoration of autologous HSC removed before the
start of chemotherapy or by allogeneic transplantation.

Identifying new anticancer drugs that do not target HSC
and their descendants is thus a priority.
HSC reside in the bone marrow in a specialized niche
composed primarily of ECM, osteoblasts, mesenchymal
stem cells, and vascular ECs. A hematopoietic microphysiological system will need to contain each of these cellular
elements and the matrix will need to be extracted from
bone marrow to ensure the presence of necessary extracellular cues. It is essential that the system will model the following: (1) the maintenance of healthy HSCs that undergo
renewal, (2) the generation of lymphoid lineage cells, (3) the
generation of erythroid lineage cells, (4) the generation of
myeloid lineage cells, and (5) the release of these cells into a
circulatory system – the ‘blood.’ Incorporation of an
immune compartment, specifically a hematopoietic compartment, into any platform of integrated microphysiological systems will provide obvious advantages in anticancer
drug-screening strategies.
Platform design considerations
Individual modules of microphysiological systems mimicking critical organ functions can be developed separately
and integrated to produce a platform for drug screening
(Figure 1(a) and (b)). Such a platform should have the following features: biocompatible, flexible, high-throughput,
reproducible design, easy fabrication, affordable, and a
small footprint.
Using soft lithography, it is possible to fabricate polydimethylsiloxane (PDMS) devices with micron range features
reproducibly and precisely. In short, the process of fabrication involves the following: a master mold is created by
photolithography on silicon wafers that are spin coated
with SU8 and PDMS is poured on the master mold.
Features of the mold are impressed on polymerized
PDMS, which can be attached to another PDMS sheet or
glass in a leakproof manner by using plasma treatment.45,47
PDMS microdevices can be designed to create highthroughput platforms and the designs can be easily altered
to incorporate tissue-specific requirements, such as absorptive interface for gut tissue. Further, PDMS devices are biocompatible, flexible, affordable, and our current designs can
be adapted to create about 100 microtissues per 75 cm2 area.
Moreover, by manipulating length and/or cross sectional
area of microfluidic channels, it is also easy to maintain
physiologic pressure drops across the tissue over time periods exceeding 2 weeks.67 Importantly, PDMS is optically
clear, offering a non-invasive system of real-time tissue imaging with a high degree of spatial resolution.
Our group has recently reported successful creation of
perfused vascular networks in PDMS microdevices by
allowing self-assembly and growth of endothelial colony
forming cell derived-endothelial cells and stromal fibroblasts in a naturally occurring ECM.45,68 These tissues
were formed in a PDMS device consisting of 0.1 mm2
tissue chamber, which was fed with microfluidic channels
on either side of the tissue chamber, which mimicked arterial and venular supply to the tissue (Figure 1(a)).
Significantly, the tissues were maintained in a medium
without exogenous addition of VEGF or bFGF (primary

growth factors for ECs and fibroblasts, respectively) and
under physiologic oxygen concentration. These studies
have shown that using microtechnology, it is possible to
achieve an intricate balance of biochemical and mechanical
cues, and cell–cell communication to generate anatomical
features of inter-connected capillary networks. Importantly,
once the microvascular network is developed and anastomosed to the PDMS microfluidic channels, the tissue is fed
only with the microvascular flow. This feature of the system
is particularly important because it allows control over morphogen delivery to tissues via the vasculature. Also, flow
through the vasculature can be controlled by simply altering the hydrostatic pressure gradient.67–69 Thus, this technology has opened a plethora of opportunities for
developing organ systems mimicking in vivo tissues for
drug screening platforms.
This technology can be extended to create vascularized
tumor, cardiac, reproductive, and other major organ systems incorporating the cells of specific organs that mimic
critical functions of the organ. An example of a microphysiological
system
module
with
appropriate

instrumentation, such as a fluid pressure sensor, pump,
and oxygenation system, is shown in Figure 1(a) and (b).
To grow microtissues in a microdevice, organ-specific cells,
ECs, and other stromal cells are initially mixed with ECM
gels and the mixture is seeded in the microdevice (Figure
1(a)). The microtissue is initially nourished by interstitial
flow controlled by a pressure gradient across the microfluidic channels. Once the microtissue is vascularized, and the
vasculature anastomoses with the high and low pressure
microfluidic lines (Figure 1(a) and (b)), the tissue is completely nourished by the vasculature.
To integrate prevascularized organ systems on an integrated drug screening platform, the modules will be
equipped with connector valves, which will allow modules
to be daisy-chained for system-wide integration
(Figure 1(a)). These modules can be connected so as to
broadly mimic the human circulation in which the tissue
chambers are connected by the circulation in parallel
(Figure 1(b)). Important considerations for integration are
compatible tissue culture media for all tissues on the platform and relative scale of the tissues. Since most primary

Figure 1 A prototype drug screening platform. (a) The microphysiological systems are developed in a central tissue chamber of individual modules. These microtissues are initially nourished by interstitial flow and later by a perfused capillary network. The medium is pumped around a microfluidic network and is oxygenated
through a bubble chamber. A pressure regulator controls ‘arterial’ pressure. Input and output channels on the arterial and venous side, respectively, allow mixing of
fresh medium into the system. Individual tissue modules can be connected like jigsaw pieces, and connector valves allow ‘anastomosis’ of microfluidic channels. (b)
Microfluidic channels are lined by EC and these anastomose with the microvessels in the tissue chamber to form a continuous vascular network linking all of the organs.
(c) An example of how the major organs with a tumor might be placed such that their perfusion is in parallel to each other. (A color version of this figure is available in the
online journal.)

culture systems need a specialized medium for cell survival, differentiation, and growth, a universal medium supplemented with organ-specific growth factors needs to be
developed. Previously, it was shown that mixing two or
more specialized growth media can be used to facilitate
function and growth of cells in co-cultures.70–72
To simulate the integrated function of various organs on
the organ-on-chip platform, it is necessary to appropriately
scale these systems, the strategies for which are recently
reviewed.73,74 The scaling is critical because the vascular
blood supply (determined as percent cardiac output of the
blood supply) per unit mass of organ varies considerably
among various organs, significantly differing the amount of
drug received by the organs. For drug screening platforms,
the appropriate scaling parameters are the blood supply per
unit mass and relative mass of an organ system with respect
to other organ systems. These are required to maintain similarity with the in vivo organs. Notably, it may not be possible
to maintain the relative mass of some of the organs, particularly skeletal muscle and adipose tissue whose masses are
greater than 500 times the mass of testis/ovaries.75 In such
cases, the morphogen or concentrations on the arterial side
of the flow of particular organ systems may be modified to
accommodate the scaling parameter.
The organ-on-chip platforms can be analyzed at molecular, cellular, tissue, and systemic level functional endpoints.
The greatest advantage of the platform material is that it is
optically clear and does not interfere with wavelengths of
light required for fluorescence or bright field imaging. This
feature allows non-invasive image-based measurement of
parameters relevant to drug-induced endpoints of pathogenesis, such as fluorescent lifetime imaging of metabolic
state,76 assessment of calcium handling using calcium sensitive proteins77 or calcium dyes,78 electrophysiology monitoring using voltage sensitive dyes,79 force–frequency
response to pacing,80 perfusion, and vascular permeability.
The organ-on-chip platform also allows easy collection of
circulating media to analyze for soluble factors.
Importantly, it is also possible to isolate each micro-organ
for genomic or proteomic analysis as each microtissue is
maintained in a separate tissue chamber.

Incorporation of other organ systems
Our device has been designed specifically to address the
effects of anticancer drugs in vascular, tumor, cardiac, and
bone marrow tissues. However, other organ systems have
also demonstrated significant response to anticancer drugs
and are important to consider as modules in future iterations of the device. The general approach and methodology of our proposed modular platform is easily
adaptable to other tissue systems. The gastrointestinal
tract (GI),81,82 liver,83 kidneys,84 nervous system,85,86 skeletal muscle,87,88 and gonads89,90 have all been reported to
have anticancer drug-related pathologies.
Key features of developing a GI module include analogs
of the small intestine (primary site of drug absorption) and
the liver (primary site of drug metabolism). Small intestine
tissue is comprised of a simple epithelium with absorptive
cells and three different secretory lineages. Mimicry of this

epithelium will require engineering of a similar epithelium
to provide selective barrier function through which circulating media can pass. This will filter drug compounds
accordingly and secrete the appropriate factors into the
tissue microenvironment. Liver tissue is complex and consists of different zones with specific enzyme activity (phase
I and phase II enzymes).91 A major factor that regulates the
enzyme activity in these zones is oxygen tension (i.e. variable distance from the closest blood vessel).92 To mimic liver
function in a small microphysiological system compartment, an oxygen gradient will need to be established
within the compartment to achieve the differential phase I
and phase II enzyme activity in hepatocytes. Directional
flow across the oxygen gradient will be necessary to
expose candidate drugs to the appropriate sequence of
enzymes to ensure that drugs are metabolized as they are
in vivo.
Kidney compartments will need to mimic the main
kidney functions of waste removal and metabolite excretion
in the urine. Renal tubule epithelial cells are especially susceptible to toxic substances and are the critical cell that
coordinates the secretion of waste products (including
metabolized drug compounds) and the reabsorption of
necessary nutrients.93 In vivo, both of these objectives are
achieved by a counter-current mass exchanger. Thus, an
engineered in vitro compartment could mimic this exchanger using microfluidics and a selectively permeable membrane, similar to that used in renal dialysis,94 coated with
renal tubule epithelial cells.
Nervous tissue modules will require blood–brain barrier
(BBB) and blood–cerebrospinal fluid barrier analogs to
simulate the specialized barrier properties that regulate
access to microglia, neurons, oligodendrocytes, and astrocytes. Attempts at BBB reconstitution have been incomplete
thus far, but the proper shear stress resulting from blood
flow, as provided by our platform, is widely regarded as a
key feature.95
A skeletal muscle module will include contractile tissue
and secretion of metabolically active factors into the vascular circuit. Appropriate secretion of metabolically active factors, such as interleukin-6, is necessary for hormonal
communication and potential effects on drug metabolism.96
In addition, the contractile tissue will require exogenous
electrical stimulation since certain anticancer drugs affect
neuromuscular activity.97
Gonad compartments will require both a testis and an
ovary model. Drug effects on the testis and ovary can be
profound and can influence not only immediate reproductive output, but can also have long-term effects on gametes.
The main components necessary to mimic are: (1) the maintenance of spermatogonial stem cells in the testis, (2) the
development of ovarian follicles in the ovary, (3) recreation
of the blood–testis barrier in males, and (4) secretion of the
sex hormones testosterone and estrogen.

Conclusion
The need for improved methods of screening for anticancer
drugs prior to clinical trials is apparent. We have developed
a strategy to create a platform that incorporates 3D tissue

modules from multiple organ systems to assess the efficacy,
as well as the potential side effects, of anticancer drugs.
These tissues are comprised entirely of human cells, are
perfused by a microvasculature, and mimic the in vivo features of vascular drug delivery and tissue response. The
tissues are incorporated into a microfluidic device that
allows control of multiple parameters that affect tissue
physiology and drug response, as well as non-invasive
monitoring of tissue state. The device is currently comprised of vascular, tumor, cardiac, and bone marrow tissues
and is designed to allow for expansion of the system to
include additional tissue modules. This in vitro approach
represents a significant advance in the ability to identify
potential adverse effects of anticancer treatment well
before they reach clinical trials.
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